CEPI, the Coalition for Epidemic Preparedness Innovations, yesterday announced a $43.5 million deal with pharmaceutical giant AstraZeneca to advance the development of a novel antibody that could ...

a trispecific antibody designed as a prophylaxis and therapeutic against SARS-CoV-2 infection. Using in-house phage libraries of naïve and synthetic humanized llama nanobodies (VHH), the Ab ...

CEPI is partnering with Astrazeneca plc to advance VHH-based multispecific antibodies targeting influenza, while Harbour Biomed Ltd. has entered into a global strategic collaboration with Astrazeneca ...

Originally derived from camelid heavy chain antibodies, single domain or VHH antibodies can bind epitopes that are inaccessible to conventional monoclonal antibodies due to their small size. Because ...

Researchers from Vicero Inc. have developed a Vincobody platform, which allows for design of novel proprietary VHH antibody fragments that possess the efficacy of dual checkpoint blockade while ...

The ImmunoPrecise antibody discovery process is determined ... or single-domain anti-body (VHH) format. Clients also have access to the company’s proprietary in-house disease and naive human ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

About VINCOBODIES VINCOBODIES are an advancement in antibody engineering ... the development of next-generation multivalent VHH VINCOBODIES to conquer unmet medical needs in cancer and immunology.